The nasal spray vaccine FluMist can now be ordered online and shipped to your door.

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door open to mRNA therapies for cancer and genetic conditions.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.

On this episode of Uncanny Valley, we dive into the heated race between two companies to build a commercial brain-computer interface.

The US almost lost its measles elimination status once. Lessons from that episode suggest it will be more difficult to avoid doing so now.

In United States v. Skrmetti, the Supreme Court ruled that Tennessee’s ban on gender-affirming care for minors was not unconstitutional—the first case of its kind on which the court has ruled.

So-called “less-lethal” weapons like those that have been used against demonstrators in Los Angeles can cause severe, lasting harm like nerve or brain damage or blindness. They can also kill.

Paradromics, a brain-computer-interface startup, inserted its brain implant in a person—briefly—in an early test of its technology.

The booming popularity of Ozempic and other GLP-1 drugs for weight loss has led to a flurry of companies vying to make new and improved anti-obesity medications.

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and a small group of human volunteers showing that its approach is safe and may be able to suppress hunger. The company presented the findings Thursday at the European Congress on Obesity and Weight Management.

“We're at a stage with obesity treatment where it's important for us to figure out, how do we now tune it to be more effective?” says Rahul Dhanda, Syntis Bio’s CEO and cofounder.

Read full article

Comments

© Peter Dazeley/Getty Images